Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne

ClinicalTrials.gov ID: NCT04582383

Public ClinicalTrials.gov record NCT04582383. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Multi-Center Comparative Effectiveness Study of Spironolactone Versus Doxycycline Hyclate for the Treatment of Acne in Women

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Acne is common illness of adolescents and young adults which is associated with substantial morbidity. While topical treatments are often sufficient for mild acne, moderate to severe acne often requires treatment with systemic medications such as oral antibiotics, hormonal therapies such spironolactone, and isotretinoin. Sebum overproduction is fundamental to the pathogenesis of acne with associated disordered keratinization and subsequent microbial colonization and inflammation resulting in the clinical manifestations of acne. Given the influence of hormones on sebum production, therapies that address these underlying hormonal factors such as spironolactone and oral contraceptive pills represent an underutilized treatment option for women with acne and could help decrease the use of long-term oral antibiotics in this patient population. The purpose of this trial is to evaluate the comparative effectiveness of spironolactone versus doxycycline hyclate (tetracycline class antibiotic) for women with acne.

Study identification

NCT ID
NCT04582383
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 4
Lead sponsor
University of Pennsylvania
Other
Enrollment
350 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
16 Years to 40 Years
Sex
Female
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 29, 2022
Primary completion
Feb 13, 2026
Completion
Jul 30, 2027
Last update posted
Aug 24, 2026

2022 – 2027

United States locations

U.S. sites
18
U.S. states
10
U.S. cities
16
Facility City State ZIP Site status
Johnson Dermatology Fort Smith Arkansas 72916
University of California San Francisco San Francisco California 94115
Cura Clinical Research Sherman Oaks California 92866
University of Miami Miami Florida 33136
New Horizon Research Center Miami Florida 33165
Dawes Fretzin Clinical Research Group Indianapolis Indiana 46250
Brigham and Women's Hospital Boston Massachusetts 02115
New York University New York New York 10016
Northwell Health North New Hyde Park New York 11042
Dermatologists of Central States Cincinnati Ohio 45242
Ohio State University Medical Center Columbus Ohio 43215
Cyn3rgy Research Gresham Oregon 97030
Oregon Health and Science University Portland Oregon 97239
Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104
University of Pennsylvania Philadelphia Pennsylvania 45209
Arlington Research Center Arlington Texas 76011
North Texas Center for Clinical Research Frisco Texas 75034
CCS Texas Houston Texas 77004

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04582383, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 24, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04582383 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →